NEW YORK, NY / ACCESSWIRE / September 26, 2017 / BioSig Technologies, Inc. (OTCQB: BSGM), a medical device company developing a
proprietary platform designed to address an unmet technology need within the $4+ billion electrophysiology (EP) marketplace, will
be presenting at this year's MicroCap Conference on October 5th in New York City.
Mr. Kenneth L. Londoner, Chairman & CEO of BioSig Technologies, will be giving the presentation and meeting with investors. The
presentation will focus on the Company's PURE EP™ System, a novel cardiac signal acquisition and display system which is engineered
to assist electrophysiologists in clinical decision making during procedures to diagnose and treat patients with abnormal heart
rates and rhythms. The presentation will also cover recent Company developments and current marketplace. To arrange a meeting with
management, please email Lora Mikolaitis at lmikolaitis@biosigtech.com.
CONFERENCE OVERVIEW AND STRUCTURE
The MicroCap Conference is an exclusive event for investors who specialize in small and microcap stocks. It is an opportunity to
be introduced to and speak with management at some of the most attractive small companies, learn from various expert panels, and
mingle with other microcap investors.
The MicroCap Conference will take place in New York City at the Essex House on October 5th. Registration will begin on Thursday
at 7:00 AM, and will last until the evening. These days will be jam-packed with company sessions, presentations, good food, and
plenty of time to network with other investors over drinks at the reception. This event does not allow service providers - only
portfolio managers, analysts, and private investors.
REGISTRATION FOR INVESTORS
To register, please go to our website (microcapconf.com/conferences/new-york-2-2017/), and click "Investor Registration."
PARTICIPATING COMPANIES
For our most updated list of companies, please go to our website (microcapconf.com/conferences/new-york-2-2017/)
MARQUEE SPONSORS
- The Special Equities Group - Maxim Group
OTHER SPONSORS
- M2 Compliance - MZ Group - Pryor Cashman - Wexler Burkhart Hirschberg & Unger - IRTH Communications - PCG
Advisory Group - CORE IR - Catalyst IR - Marcum
News Compliments of ACCESSWIRE.
About BioSig Technologies
BioSig Technologies is a medical device company developing a proprietary technology platform designed to improve the $4+ billion
electrophysiology (EP) marketplace (www.biosigtech.com). Led by a proven management team and a veteran, independent Board of
Directors, Minneapolis-based BioSig Technologies is preparing to commercialize its PURE EP™ System. The technology has been
developed to address an unmet need in a large and growing market.
The PURE EP System is a novel cardiac signal acquisition and display system which is engineered to assist electrophysiologists
in clinical decision making during procedures to diagnose and treat patients with abnormal heart rates and rhythms. BioSig's main
goal is to deliver technology to improve upon catheter ablation treatments for prevalent and deadly arrhythmias. BioSig has
partnered with Minnetronix on technology development.
Forward-looking Statements
This press release contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will,"
"plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential," or similar words.
Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various
known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified
and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such
risks and uncertainties include, without limitation, risks and uncertainties associated with (i) our inability to manufacture our
product candidates on a commercial scale on our own, or in collaboration with third parties; (ii) difficulties in obtaining
financing on commercially reasonable terms; (iii) changes in the size and nature of our competition; (iv) loss of one or more key
executives or scientists; and (v) difficulties in securing regulatory approval to market our product candidates.. More detailed
information about the Company and the risk factors that may affect the realization of forward looking statements is set forth in
the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its
Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's web
site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a
result of new information, future events or otherwise.
Contact:
Name: Lora Mikolaitis Phone: 310-948-7200 Email: lmikolaitis@biosigtech.com
FOR MORE INFORMATION
Please visit: www.microcapconf.com Or, contact Tony Yu at tony@microcapconf.com.
SOURCE: BioSig Technologies, Inc.
